A maker of over-the-counter self-care products, Perrigo supplies store-brand medicines to retailers and also sells its own brands like Opill®, Mederma®, Compeed®, and Solpadeine® across North America and Europe. The company traces back to 1887, when Michigan general-store owner Luther Perrigo began packaging medicines and household goods for other country stores — and pioneered the private-label idea by printing each store's own name on the labels. The company still bears his name today.
Perrigo appoints Salman Amin and Omer Gajial to its Board, effective June 30, 2026
The Board increased its size from 8 to 10 members in connection with the appointments.
Show detailsHide details
On June 30, 2026, Perrigo Company plc appointed Salman Amin and Omer Gajial as independent directors, effective the same day.
Mr. Amin will serve on the Audit Committee and the Nominating and Governance Committee; Mr. Gajial will serve on the Talent and Compensation Committee.
Mr. Amin, age 66, is a former CEO of pladis Global with over 30 years in consumer products; Mr. Gajial, age 52, is CEO of GoTo Foods and former EVP at Albertsons Companies.
Each new director will receive standard non-employee director compensation as described in the proxy statement filed March 20, 2026.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Perrigo CEO Patrick Lockwood-Taylor resigns; Albert A. Manzone named Interim CEO
Patrick Lockwood-Taylor resigned effective June 7, 2026, as President, CEO, and Board member after the Board determined his personal conduct violated the Company's Code of Conduct and core values.
Show detailsHide details
The Board reduced its size from 9 to 8 directors and appointed Albert A. Manzone, a current director and Audit Committee member, as Interim President and CEO, effective immediately.
A comprehensive search for a permanent President and CEO has been initiated.
Manzone will step down from the Audit Committee during his interim service and will also step down as Deputy CEO of Monte-Carlo Société des Bains de Mer.
Compensatory terms for Manzone's interim role have not been finalized; disclosure will be provided in an amendment to this 8-K within four business days.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Perrigo reports Q1 2026 results: All In net sales $969M, reported diluted EPS $(2.81), maintains FY2026 outlook
Reported net sales for Q1 2026 were $969 million, down 7.2% year over year; Core net sales were $842 million, down 8.3%.
Show detailsHide details
Reported diluted EPS was $(2.81), primarily due to a $330.8 million goodwill impairment charge; All In adjusted diluted EPS was $0.43, down 28.3%.
All In adjusted gross margin was 37.6% (down 340 bps) and adjusted operating margin was 11.6% (down 240 bps).
Specialty Care segment net sales grew 4.0% and segment operating income grew 31.4%, driven by Women's Health brands.
Company completed divestiture of Dermacosmetics business after quarter end with upfront proceeds of approximately €306 million, and maintained full-year 2026 outlook.
Cash flow from operations was an outflow of $114 million in Q1 2026, with capital expenditures of $14 million and dividends of $40 million.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Perrigo shareholders approve 2026 Long-Term Incentive Plan at Annual Meeting
The 2026 Plan was previously approved by the Board on February 18, 2026 and became effective immediately upon shareholder approval.
Show detailsHide details
At the April 30, 2026 Annual Meeting, shareholders approved the Perrigo Company plc 2026 Long-Term Incentive Plan, which replaces the 2019 plan.
All eight director nominees were elected, with votes ranging from 92,116,246 for Albert A. Manzone to 106,601,125 for Kevin Egan.
Shareholders ratified Ernst & Young LLP as independent auditor for 2026 and approved the advisory vote on executive compensation.
Shareholders also renewed the Board's authority to issue shares and opt out of statutory pre-emption rights under Irish law.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Perrigo announces new product-category-based reporting segments and recast financials
Perrigo changed its reporting segments from geographic to product-category based, effective Q1 2026, with segments Self Care, Specialty Care, and Infant Formula, plus 'All Other'.
Show detailsHide details
The company recast select financial metrics for the new segments for fiscal years 2024 and 2025, furnished as Exhibit 99.1.
For fiscal year 2025, consolidated net sales were $4,253.1 million, down from $4,373.4 million in 2024.
For fiscal year 2025, consolidated adjusted operating income was $622.3 million, with Self Care contributing $472.6 million, Specialty Care $200.5 million, and Infant Formula $9.6 million.
The company also changed its primary segment profitability measure from segment operating income to segment adjusted operating income.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits